# Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities

> **NCT04525300** · PHASE3 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 300 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04525300
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-24
- **Primary completion:** 2022-06
- **Final completion:** 2022-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525300, "Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04525300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*